16:50 15 May 2015
There are a lot of studies that indicate a major cause of morbidity and death in cancer patients are the metastasis that develop from the primary tumor. Yet a great majority of preclinical research only assesses primary tumors and the inhibition of their growth. These models are often used for drug efficacy and toxicity studies that may eventually lead to clinical trials. But how can we use a model that doesn’t monitor metastasis when that is a key part of the tumorgenesis that significantly contributes to death. How do we better model Metastasis? How will this impact our clinical trials?